Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
J Pharm Biomed Anal ; 167: 123-131, 2019 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-30771645

RESUMEN

The present study focuses on identifying the degradation profile and pathways of unknown impurities from beclomethasone dipropionate (BDP) topical cream formulation reported under accelerated stability conditions. Six degradation impurities were observed during the accelerated stability testing of BDP topical cream formulation, and these thermally labile degradation impurities were primarily identified using a simple, effective and mass compatible isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection method. The degradation impurities found in this sample were of very low concentration levels, thus the concentration of these impurities in the sample was enriched by mimicking the thermal degradation conditions to structurally elucidate the unknown impurities. These BDP thermal degradation impurities were isolated using preparative liquid chromatography and followed by pre-concentration using rota-vapour. Further, the collected thermal degradation impurities were characterized using ESI-MS, and the major impurity was identified using 1H and C13 NMR spectroscopy, and DEPT technique. Plausible degradation pathway and mechanism of each impurity from BDP has been proposed based on the obtained mass and NMR spectral data. Thus, the present method is simple and suitable to be applied towards BDP assay in various formulations, and also to investigate the thermal stability and degradation kinetics of the final drug product.


Asunto(s)
Beclometasona/análisis , Contaminación de Medicamentos , Glucocorticoides/análisis , Crema para la Piel/análisis , Beclometasona/normas , Cromatografía Líquida de Alta Presión , Estabilidad de Medicamentos , Glucocorticoides/normas , Espectroscopía de Resonancia Magnética , Crema para la Piel/normas , Espectrometría de Masa por Ionización de Electrospray
3.
Int J Pharm ; 496(2): 342-50, 2015 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-26456265

RESUMEN

A novel "slurry method" was described for the preparation of proliposome powders using soya phosphatidylcholine (SPC) with cholesterol (1:1) and for incorporation of beclometasone dipropionate (BDP) at 2mole% of the total lipid phase. Proliposomes made with a range of lipid to sucrose carrier ratios were studied in terms of surface morphology using scanning electron microscopy (SEM) and thermal properties using differential scanning calorimetry (DSC). Following hydration of proliposomes, the resultant vesicles were compared to liposomes made using the traditional proliposome method, in terms of vesicle size and drug entrapment efficiency. SEM showed that sucrose was uniformly coated with lipid regardless of lipid to carrier ratio. Liposomes generated using the slurry proliposome method tended to have smaller median size than those generated with the conventional proliposome method, being in the range of 4.72-5.20µm and 5.89-7.72µm respectively. Following centrifugation of liposomes using deuterium oxide (D2O) as dispersion medium, vesicles entrapping BDP were separated as a floating creamy layer, whilst the free drug was sedimented as crystals. Drug entrapment was dependent on formulation composition and preparation method. When 1:15 w/w lipid to carrier was used, liposomes generated using the slurry method had an entrapment efficiency of 47.05% compared to 18.67% for those generated using the conventional proliposome method. By contrast, liposomes made by the thin-film hydration method had an entrapment efficiency of 25.66%. DSC studies using 50mole% BDP demonstrated that the drug was amorphous in the proliposome formulation and tended to crystallize on hydration, resulting in low drug entrapment. In conclusion, a novel approach to the preparation of proliposomes using a slurry method has been introduced, offering higher entrapment for BDP than liposomes made using the conventional proliposome method and those prepared by thin-film hydration technique.


Asunto(s)
Beclometasona/síntesis química , Química Farmacéutica/métodos , Profármacos/síntesis química , Beclometasona/análisis , Cromatografía Líquida de Alta Presión/métodos , Liposomas , Microscopía Electrónica de Rastreo/métodos , Polvos , Profármacos/análisis
4.
Spectrochim Acta A Mol Biomol Spectrosc ; 128: 127-36, 2014 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-24662761

RESUMEN

Spectrophotometric and TLC-spectrodensitometric methods were developed and validated for the simultaneous determination of beclomethasone dipropionate (BEC) and salbutamol (SAL). The spectrophotometric methods include dual wavelength, ratio difference, constant center coupled with a novel method namely, spectrum subtraction and mean centering with mean percentage recoveries and RSD 99.72±1.07 and 99.70±1.12, 100.25±1.12 and 99.89±1.12, 99.66±1.85 and 99.19±1.32, 100.74±1.26 and 101.06±0.90 for BEC and SAL respectively. The TLC-spectrodensitometric method was based on separation of both drugs on TLC aluminum plates of silica gel 60 F254, using benzene: methanol: triethylamine (10:1.5:0.5 v/v/v) as a mobile phase, followed by densitometric measurements of their bands at 230 nm. The mean percentage recoveries and RSD were 99.07±1.25 and 101.35±1.50 for BEC and SAL respectively. The proposed methods were validated according to ICH guidelines and were applied for the simultaneous analysis of the cited drugs in synthetic mixtures and pharmaceutical preparation. The methods were found to be rapid, specific, precise and accurate and can be successfully applied for the routine analysis of BEC and SAL in their pharmaceutical formulation with no need for prior separation. The results obtained were statistically compared to each other and to that of the reported HPLC method. The statistical comparison showed that there is no significant difference regarding both accuracy and precision.


Asunto(s)
Albuterol/análisis , Beclometasona/análisis , Cromatografía en Capa Delgada/métodos , Espectrofotometría/métodos
5.
J Chromatogr Sci ; 52(10): 1255-66, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24515312

RESUMEN

Fixed dose combination containing beclomethasone dipropionate (BDP) and formoterol fumarate dihydrate (FFD) is used in the treatment of asthma in form of dry powder inhaler. Two methods are described for the simultaneous determination of BDP and FFD in commercial rotacap formulation. The first method was based on HPTLC separation of the two drugs followed by densitometric measurements of their spots at 220 nm. The separation was carried out on Merck HPTLC aluminum sheets precoated with silica gel 60F254 using hexane:ethyl acetate:methanol:formic acid (2.0:2.5:2.0:0.2, v/v/v/v) as mobile phase. The linearity was found to be in the range of 2.4-8.4 µg/spot and 80-280 ng/spot for BDP and FFD, respectively. The second method was based on HPLC separation of the two drugs on the reversed phase Enable HPLC Analytical C18 G 120Å (250 × 4.6 mm, 5 µm) column at ambient temperature using a mobile phase consisting of methanol:acetonitrile:phosphate buffer adjusted to pH 3.6 using orthophosphoric acid (65:25:10, v/v/v). Quantitation was achieved with UV detection at 220 nm based on peak area with linear calibration curves at concentration ranges of 10-200 and 0.3-6.0 µg/mL for BDP and FFD, respectively. Both methods were validated in terms of precision, robustness, recovery and limits of detection and quantitation. The robustness of both methods was assessed using experimental design and results were analyzed by statistical and graphical approaches. Rotacaps formulation containing BDP (200/400 µg) and FFD (6 µg) were successfully quantified using the proposed methods. The proposed methods can be used as sensitive, precise, accurate and robust methods for quantification of BDP and FFD in Rotacaps.


Asunto(s)
Beclometasona/análisis , Cromatografía Líquida de Alta Presión/métodos , Cromatografía en Capa Delgada/métodos , Etanolaminas/análisis , Cápsulas/química , Fumarato de Formoterol , Límite de Detección , Modelos Lineales , Reproducibilidad de los Resultados
6.
J Chromatogr A ; 1311: 11-20, 2013 Oct 11.
Artículo en Inglés | MEDLINE | ID: mdl-24011726

RESUMEN

Glucocorticoids contamination has become a big environmental issue in China and other developing countries, due to increasing needs in medical prescription and farming. However, no highly sensitive and precise methods have been reported to quantify glucocorticoids so far. In the past several years, supramolecular solvent-based vortex-mixed microextraction (SS-BVMME) has been shown to be effective. However, the mechanism of SS-BVMME is still unknown. In this report, a novel method has been proposed for rapid quantification of trace amount of glucocorticoids, beclomethasone dipropionate (BD), hydrocortisone butyrate (HB) and nandrolone phenylpropionate (NPP) in water samples from the Green Lake. This method is simple, safe and cost effective. It contains two steps: supramolecular solvent-based vortex-mixed microextraction (SS-BVMME) technique and high performance liquid chromatography (HPLC) analysis. First, ionic liquids 1-butyl-3-methylimidazolium tetrafluoroborate ([BMIM]BF4) and n-butanol were mixed to form the supramolecular solvent. After mixing the supramolecular solvent with an aqueous sample to test, a homogenous mixture was formed immediately. BD, HB and NPP were then extracted based on their binding interactions, particularly hydrogen bond formed between their hydroxyl group and the supramolecular solvent. The overall process of sample preparation took only 20min and more than 5 samples could be simultaneously prepared. The minimum detectable concentrations of samples in this method were 0.09925, 0.5429 and 2.428ngmL(-1) for BD, HB and NPP, respectively. Product recoveries ranged from 88% to 103% with relative standard deviations from 0.6% to 4%. For the first time, we report that hydrogen bond plays a key role in SS-BVMME. We also improve the sensitivity significantly to quantify glucocorticoids, which may greatly benefit environmental safety management in China.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Glucocorticoides/análisis , Lagos/análisis , Microextracción en Fase Líquida/métodos , Contaminantes Químicos del Agua/análisis , 1-Butanol/química , Beclometasona/análisis , China , Hidrocortisona/análogos & derivados , Hidrocortisona/análisis , Imidazoles/química , Líquidos Iónicos/química , Límite de Detección , Nandrolona/análogos & derivados , Solventes
7.
Respir Investig ; 50(2): 54-61, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22749251

RESUMEN

BACKGROUND: The influence of dentures on residual inhaled corticosteroids (ICSs) in the mouths of elderly asthmatic patients and the appropriate time for gargling after inhaling ICSs are unclear. METHODS: Twenty elderly patients in whom moderate persistent asthma was stably controlled using fluticasone propionate Diskus (FP, n = 10) or hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP, n = 10) for more than 3 months and who wore dentures daily were switched to the other type of ICS for 4 weeks in a crossover manner. The residual amount of each ICS in their mouths after inhalation was measured along with determination of peak inspiratory flow (PIF) and pharyngeal culture for detecting Candida albicans. RESULTS: The total amounts of residual ICSs in gargling fluids (µg) with HFA-BDP were significantly greater than those with FP (15.6 ± 14.6 vs. 11.5 ± 13.8, p = 0.028). The residual amounts of HFA-BDP were significantly greater in the patients with complete dentures than in those with partial dentures. The residual amounts of FP were significantly correlated with the PIF values in the FP treatment (p = 0.013) but not in the HFA-BDP treatment (p = 0.202). No residual ICSs remained after the third gargling in either treatment. The occurrence of candidiasis during the HFA-BDP period was significantly higher than that during the FP treatment (p = 0.046). CONCLUSION: The dentures of elderly asthmatics affect the oral residues of ICSs and occurrence of candidiasis in HFA-BDP treatment; meanwhile, the PIF values affected these factors in FP treatment. Three times gargling after inhaling ICSs is required.


Asunto(s)
Androstadienos/efectos adversos , Androstadienos/análisis , Asma/tratamiento farmacológico , Beclometasona/efectos adversos , Beclometasona/análisis , Broncodilatadores/efectos adversos , Broncodilatadores/análisis , Dentaduras/efectos adversos , Hidrocarburos Fluorados/efectos adversos , Hidrocarburos Fluorados/análisis , Boca/química , Administración por Inhalación , Anciano , Anciano de 80 o más Años , Androstadienos/administración & dosificación , Beclometasona/administración & dosificación , Broncodilatadores/administración & dosificación , Candidiasis Bucal/etiología , Candidiasis Bucal/prevención & control , Femenino , Fluticasona , Humanos , Hidrocarburos Fluorados/administración & dosificación , Masculino , Antisépticos Bucales
8.
Analyst ; 135(6): 1259-67, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20498877

RESUMEN

Aerosol drugs dominate a significant share of pharmaceutical preparations on the market. A novel sensitive method utilizing nano extractive electrospray ionization mass spectrometry (nanoEESI-MS) has been developed for the rapid analysis of aerosol drug samples with quantitative information. Without any sample pretreatment, aerosol drugs were manually sprayed into the primary ion plume created by a nano electrospray emitter for direct ionization under ambient conditions. The analyte ions of interest were guided into an ion trap mass spectrometer for tandem mass analysis. The active ingredients of various aerosol drugs, such as econazole nitrate, beclomethasone dipropionate, binary mixture of methyl salicylate and diphenhydramine, terbutaline, and salbutamol, were rapidly detected using nanoEESI-MS. A single sample analysis could be completed within 1.2 s. Tandem mass spectrometry was used to confirm the identification of important compounds in each aerosol drug sample. Reasonable relative standard deviation (RSD = 6.39%, n = 13) and acceptable sensitivity (10 ppt, 100 muL) were found for the salbutamol aerosol sample, which suggests that nanoEESI-MS has the quantitative capacity for analyzing complex pharmaceutical samples. This method was further extended to study the thermal decomposition process of salbutamol, showing that the degradation kinetics of salbutamol can be conveniently tracked. Our data demonstrate that nanoEESI tandem mass spectrometry is a fast and sensitive technique for the analysis of aerosol drug preparations, showing promising applications in pharmacology studies and in situ analysis of aerosol drugs on the market.


Asunto(s)
Gases/química , Preparaciones Farmacéuticas/química , Espectrometría de Masa por Ionización de Electrospray/métodos , Agonistas Adrenérgicos beta/análisis , Albuterol/análisis , Antialérgicos/análisis , Antiinflamatorios/análisis , Antifúngicos/análisis , Antirreumáticos/análisis , Beclometasona/análisis , Difenhidramina/análisis , Econazol/análisis , Nanotecnología , Salicilatos/análisis , Espectrometría de Masa por Ionización de Electrospray/instrumentación , Espectrometría de Masas en Tándem , Terbutalina/análisis
9.
J Chromatogr A ; 1178(1-2): 248-55, 2008 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-18054945

RESUMEN

Capillary electrophoretic (CE) methods were used for the quantitative determination of model drugs [salbutamol sulphate (SS), sodium cromoglycate (SCG) and beclomethasone dipropionate (BDP)] in poly(D,L-lactic acid) (PLA) nanoparticles, which were prepared by the nanoprecipitation method. Zeta potential and size distribution of the nanoparticles were determined by electrophoretic mobility determinations and photon correlation spectroscopy, respectively. Interactions between the drugs, the PLA nanoparticles and the fused-silica capillary were investigated by electrokinetic capillary chromatography (EKC). A quantitative CE method was developed for salbutamol sulphate and sodium cromoglycate, and the linearity and repeatability of migration times, peak areas and peak heights were determined. Microemulsion electrokinetic chromatography was used for the quantitative determination of beclomethasone dipropionate. According to this study, the applied electromigration techniques were suitable for the interaction, drug entrapment and dissolution studies of pharmaceutical nanoparticles. The results suggest that even quantitation of the drug located inside the nanoparticles was possible. Encapsulation of the more hydrophilic model drugs (SS, SCG) in the PLA nanoparticles was less efficient than in the case of BDP.


Asunto(s)
Portadores de Fármacos , Electroforesis Capilar , Ácido Láctico , Nanopartículas , Preparaciones Farmacéuticas/análisis , Polímeros , Albuterol/análisis , Beclometasona/análisis , Cromolin Sódico/análisis , Portadores de Fármacos/análisis , Microscopía Electrónica de Rastreo , Nanopartículas/análisis , Nanopartículas/ultraestructura , Preparaciones Farmacéuticas/aislamiento & purificación , Poliésteres
10.
Pharm Res ; 24(5): 934-45, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17372686

RESUMEN

PURPOSE: This study was conducted to evaluate the feasibility of using Raman chemical imaging (i.e., Raman imaging microspectroscopy) to establish chemical identity, particle size and particle size distribution (PSD) for a representative corticosteroid in aqueous nasal spray suspension formulations. MATERIALS AND METHODS: The Raman imaging PSD protocol was validated using polystyrene (PS) microsphere size standards (NIST-traceable). A Raman spectral library was developed for the active and inactive compounds in the formulation. Four nasal sprays formulated with beclomethasone dipropionate (BDP) ranging in size from 1.4 to 8.3 microm were imaged by both Raman and brightfield techniques. The Raman images were then processed to calculate the PSD for each formulation. RESULTS: Within each region examined, active pharmaceutical ingredient (API) particles are unambiguously identified and the total number of those particles, particle size and PSD of API free of excipients and PSD of API particles adhered to other excipients are reported. CONCLUSIONS: Good statistical agreement is obtained between the reported and measured sizes of the PS microspheres. BDP particles were clearly distinguishable from those of excipients. Raman chemical imaging (RCI) is able to differentiate between and identify the chemical makeup of multiple components in complex BDP sample and placebo mixtures. The Raman chemical imaging method (coupled Raman and optical imaging) shows promise as a method for characterizing particle size and shape of corticosteroid in aqueous nasal spray suspension formulations. However, rigorous validation of RCI for PSD analysis is incomplete and requires additional research effort. Some specific areas of concern are discussed.


Asunto(s)
Tamaño de la Partícula , Preparaciones Farmacéuticas/análisis , Espectrometría Raman/métodos , Aerosoles , Beclometasona/análisis , Beclometasona/química , Glucocorticoides/análisis , Glucocorticoides/química , Microscopía Electrónica de Transmisión , Microesferas , Preparaciones Farmacéuticas/química , Soluciones Farmacéuticas/química , Desarrollo de Programa , Análisis de Regresión , Reproducibilidad de los Resultados , Espectrometría Raman/normas , Suspensiones , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Agua/química
11.
Eur Respir J ; 29(2): 299-306, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17005581

RESUMEN

The aim of the present study was to measure airway, oropharyngeal and gastrointestinal deposition of (99m)Tc-labelled hydrofluoroalkane-beclomethasone dipropionate after inhalation via a pressurised metered-dose inhaler and spacer (Aerochamber Plus) in asthmatic children. A group of 24 children (aged 5-17 yrs) with mild asthma inhaled the labelled drug. A total of 12 children took five tidal breaths after each actuation (tidal group). The other 12 children used a slow maximal inhalation followed by a 5 - 10-s breath-hold (breath-hold group). Simultaneous anterior and posterior planar gamma-scintigraphic scans (120-s acquisition) were recorded. For the tidal group, mean+/-sd lung deposition (% ex-actuator, attenuation corrected) was 35.4+/-18.3, 47.5+/-13.0 and 54.9+/-11.2 in patients aged 5-7 (n = 4), 8-10 (n = 4) and 11-17 yrs (n = 4), respectively. Oropharyngeal and gastrointestinal deposition was 24.0+/-10.5, 10.3+/-4.4 and 10.1+/-6.2. With the breath-hold technique, lung deposition was 58.1+/-6.7, 56.6+/-5.2 and 58.4+/-9.2. Oropharyngeal and gastrointestinal deposition was 12.9+/-3.2, 20.1+/-9.5 and 20.8+/-8.8. Inhalation of the extrafine formulation with the breath-hold technique showed significantly improved lung deposition compared with tidal breathing across all ages. Oropharyngeal and gastrointestinal deposition was markedly decreased, regardless of which inhalation technique was applied, compared with a previous paediatric study using the same formulation delivered via a breath-actuated metered-dose inhaler.


Asunto(s)
Antiasmáticos/farmacocinética , Asma/tratamiento farmacológico , Beclometasona/análogos & derivados , Beclometasona/farmacocinética , Pulmón/metabolismo , Inhaladores de Dosis Medida , Administración por Inhalación , Adolescente , Aerosoles , Antiasmáticos/administración & dosificación , Beclometasona/administración & dosificación , Beclometasona/análisis , Niño , Preescolar , Femenino , Tracto Gastrointestinal/diagnóstico por imagen , Tracto Gastrointestinal/metabolismo , Humanos , Pulmón/diagnóstico por imagen , Masculino , Orofaringe/diagnóstico por imagen , Orofaringe/metabolismo , Cintigrafía , Distribución Tisular
12.
Int J Pharm ; 302(1-2): 154-65, 2005 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-16102928

RESUMEN

In this study, a novel laser diffraction particle size analysis dispersion system, capable of sizing particles in situ within suspension hydrofluoroalkane (HFA) pressurised metered dose inhalers (pMDIs), was developed and tested. The technique was compared to four indirect particle sizing methods commonly used to determine the size of particles suspended in HFA pMDIs. The median volume diameter obtained using laser diffraction of both the salbutamol sulphate and fluticasone propionate suspended either in 2H, 3H-decafluoropentane or perfluoropentane (employed as surrogate propellants) was over one-order of magnitude larger than the particle sizes of the drugs suspended in HFA 134a. In contrast, the "in-flight" particle size using the Sympatec inhaler 2000 laser diffraction equipment undersized the particles, predicting higher delivery efficacy compared to the other sizing methods. However, the size of particles suspended in HFAs derived using the novel pressurised dispersion system, showed a linear correlation with the impaction results, r2=0.8894 (n=10). The novel pressure cell sizing technique proved to be simple to use, has the ability to be automated and was accurate, suggesting it could be an essential tool in the development of new suspension-based pMDI formulations.


Asunto(s)
Aerosoles/análisis , Hidrocarburos Fluorados/análisis , Inhaladores de Dosis Medida/normas , Propelentes de Aerosoles/análisis , Albuterol/análisis , Androstadienos/análisis , Beclometasona/análisis , Diseño de Equipo/métodos , Fluticasona , Rayos Láser , Tamaño de la Partícula , Reproducibilidad de los Resultados , Suspensiones/análisis , Tecnología Farmacéutica/métodos
13.
Int J Pharm ; 292(1-2): 201-9, 2005 Mar 23.
Artículo en Inglés | MEDLINE | ID: mdl-15725567

RESUMEN

A new on-line reverse phase HPLC method for determining the solubility of compounds in propellant based metered dose inhaler (MDI) formulations was compared with a conventional method. The new method employs a direct injection from a MDI vial into the needle injector port of a manual injector. To evaluate the two methods, beclomethasone dipropionate (BDP), 5,5-diphenyl hydantoin and 3,3'-diindolylmethane, were used as model compounds in propellant HFA-134a. Comparison was performed by analyzing known and unknown concentrations of BDP in various combinations of HFA-134a and ethanol. In addition, the solubility of 5,5-diphenyl hydantoin and 3,3'-diindolylmethane were determined in HFA-134a using both the new and the conventional methods. The two methods were found to be in good agreement with each other, with the new direct injection technique offering enhanced precision and accuracy along with considerable reduction in analysis time.


Asunto(s)
Propelentes de Aerosoles/análisis , Solubilidad , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/tendencias , Propelentes de Aerosoles/química , Beclometasona/análisis , Combinación de Medicamentos , Indoles/química , Inhaladores de Dosis Medida , Fenitoína/análisis , Tecnología Farmacéutica/instrumentación
14.
Eur J Pharm Biopharm ; 58(3): 595-606, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15451534

RESUMEN

The aim of this study was to characterize the physical properties of spray dried lactose in the presence of different polyethylene glycols (PEG 400, PEG 3000 and PEG 6000) and to evaluate their performance as carriers for dry powder inhaler (DPI) formulations. The efficiency of spray dried lactose/PEG carriers in aerosolisation of beclomethasone dipropionate (BD), a model hydrophobic drug, was compared to Pharmatose 325 M (L325), spray dried lactose alone (SDL), and also a sieved (< 38 microm) fraction of alpha-lactose monohydrate (SL). In vitro deposition analysis was performed using a twin stage liquid impinger at a flow rate of 60 l/min through a Spinhaler. The deposition profiles of the drug from binary formulations composed of BD and spray dried lactose/PEG carriers were also compared to ternary formulations containing large and fine lactose carriers. Differential scanning calorimetry and X-ray diffraction data showed the presence of alpha-anhydrous lactose in spray dried lactose/PEG crystalline powders. Spray drying of lactose in the presence of PEG 400 resulted in the production of a powder (SDL-PEG400) with lower alpha-lactose monohydrate content, and also smaller particle size distribution than those obtained in the presence of PEG 3000 (SDL-PEG3000) or PEG 6000 (SDL-PEG6000). All formulations showed different deposition profiles, except those containing SDL-PEG3000 or SDL-PEG6000 which exhibited similar data. The fine particle fraction of aerosolised BD varied from 6.26 +/- 1.07 (for L325) to 25.87 +/- 5.33 (for SDL-PEG3000). All deposition profiles of BD aerosolised from SDL-PEG3000 were significantly higher (P < 0.01) than those produced by binary and ternary formulations containing L325, a coarse lactose commercially available for DPI formulations. The differences observed in deposition data for various carriers were interpreted according to their physical properties. It was concluded that particle size distribution, morphology and specific surface texture of SDL-PEG3000 and SDL-PEG6000 were important factors influencing their efficiency as small carriers for DPI formulations.


Asunto(s)
Beclometasona/química , Portadores de Fármacos/química , Lactosa/química , Polietilenglicoles/química , Aerosoles , Beclometasona/análisis , Portadores de Fármacos/análisis , Lactosa/análisis , Polietilenglicoles/análisis
15.
Pulm Pharmacol Ther ; 17(4): 233-8, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15219268

RESUMEN

Indirect assessments have shown a superior lung deposition of HFA-BDP (Ventolair/Qvar) compared to CFC-BDP (Aerobec). The aim of this study was to assess the concentrations of BDP and its metabolite 17-BMP in airways and peripheral tissue from resected lung specimens after inhalation of these BDP formulations. Immediately prior to surgery for lung cancer, 10 patients inhaled 1000 microg of either CFC-BDP (n = 5) or HFA-BDP (n = 5) Mouthwash was collected after inhalation, and serum before, during, and after surgery. There was no significant difference between CFC and HFA in the concentration of 17-BMP in bronchi (median, 4365 vs 4121 pg/g tissue). After CFC, concentrations of 17-BMP were lower in peripheral tissue (1424 vs 2089 pg/g; ANCOVA, p = 0.001) and in serum taken immediately after inhalation (688 vs 1219 pg/ml, p < 0.01). Furthermore, the CFC group showed a higher concentration of BDP in the mouthwash (17,660 vs 1320 ng/ml, p < 0.05), but the concentration of 17-BMP was lower (452 vs 1028 ng/ml, n.s.). These findings indicate a predominantly peripheral deposition of HFA-BDP, in line with previous data. They also provide evidence for a faster uptake and metabolism of HFA-BDP, probably because BDP is dissolved in HFA and has a smaller particle size distribution than the CFC suspensions.


Asunto(s)
Propelentes de Aerosoles/química , Beclometasona/análogos & derivados , Beclometasona/metabolismo , Beclometasona/farmacocinética , Clorofluorocarburos/química , Glucocorticoides/farmacología , Hidrocarburos Fluorados/química , Administración por Inhalación , Adulto , Anciano , Beclometasona/administración & dosificación , Beclometasona/análisis , Bronquios/química , Portadores de Fármacos , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/análisis , Humanos , Pulmón/química , Masculino , Persona de Mediana Edad , Tamaño de la Partícula , Factores de Tiempo , Distribución Tisular
16.
AAPS J ; 6(4): e32, 2004 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-15760097

RESUMEN

Scanning near-infrared Raman microscopy has been used to map aerosol particulate deposits produced from pressurized metered-dose inhalers (pMDI). A commercially available combination asthma therapy pMDI (Ventide, Allen and Hanbury, UK), containing salbutamol and beclometasone dipropionate, was analyzed by conventional in vitro quantitative analysis and scanning Raman microscopy. Raman maps, taken from Andersen cascade impactor plate stages 3 and 5 (over 100 x 100 microm areas) suggested good correlation with chemical analysis of the respective stages. Scanning Raman microscopy allows visual differentiation between formulation components (not possible using conventional imaging techniques), while potentially allowing chemical quantification.


Asunto(s)
Inhaladores de Dosis Medida , Espectrometría Raman/métodos , Aerosoles/análisis , Albuterol/administración & dosificación , Albuterol/análisis , Antiasmáticos/administración & dosificación , Antiasmáticos/análisis , Beclometasona/administración & dosificación , Beclometasona/análisis , Microscopía Electrónica de Rastreo , Presión
17.
J Pharm Pharmacol ; 55(8): 1055-61, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12956894

RESUMEN

The particle size distributions of beclometasone dipropionate delivered from Becotide and Respocort inhalers after single and multiple actuations were investigated using the Andersen Mark II Cascade impactor and the drug was quantified using high performance liquid chromatography. The fine particle mass and the mass median aerodynamic diameter were calculated. An apparent increase in mass median aerodynamic diameter was observed when the number of actuations increased. In addition, the fine particle mass decreased as the number of actuations increased. When performing and analysing cascade impaction study data differences between single versus multiple actuations must be considered. Regulatory guidelines should be amended to stipulate the number of actuations to be loaded into devices used to evaluate the particle size distribution of inhaled aerosol products.


Asunto(s)
Beclometasona/administración & dosificación , Inhaladores de Dosis Medida/normas , Nebulizadores y Vaporizadores , Tamaño de la Partícula , Administración Intranasal , Aerosoles , Beclometasona/análisis , Cromatografía Liquida/métodos , Sistemas de Liberación de Medicamentos
18.
J Mass Spectrom ; 38(8): 823-38, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12938103

RESUMEN

Beclomethasone dipropionate (BDP) is a potent pro-drug to beclomethasone (BOH) and is used in the treatment of chronic and acute respiratory disorders in the horse. The therapeutic dose of BDP (325 microg per horse) by inhalation results in very low plasma and urinary concentrations of BDP and its metabolites that pose a challenge to detection and confirmation by equine forensic laboratories. To solve this problem, a method involving the use of a liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) was developed for the detection, confirmation and quantification of the analytes in equine samples. Ammonium formate or acetate buffer added to LC mobile phase favored the formation of [M + H](+) ions from BDP and its metabolites, whereas formic acid led to the formation of sodium and potassium adduct ions ([M + Na](+), [M + K](+)) together with [M + H](+) ions. Acetonitrile, on the other hand, favored the formation of abundant solvent adduct ions [M + H + CH(3)CN](+) with the analytes under electrospray ionization (ESI) and atmospheric pressure chemical ionization conditions. In contrast, methanol formed much less solvent adduct ions than acetonitrile. The solvent adduct ions were thermally stable and could not be completely desolvated under the experimental conditions, but they were very fragile to collision-induced dissociation (CID). Interestingly, these solvent adduct ions were observed on a triple-quadrupole mass spectrometry but not on an ion trap instrument where helium used as a damping gas in the ion trap might cause the solvent adduct ions desolvated by collision. By CID studies on the [M + H](+) ions of BDP and its metabolites, their fragmentation paths were proposed. In equine plasma at ambient temperature over 2 h, BDP and B21P were hydrolyzed in part to B17P and BOH, respectively, but B17P was not hydrolyzed. Sodium fluoride added to equine plasma inhibited the hydrolysis of BDP and B21P. The matrix effect in ESI was evaluated in equine plasma and urine samples. The method involved the extraction of BDP and its metabolites from equine plasma and urine samples by methyl tert-butyl ether, resolution on a C(8) column with a mobile phase gradient consisting of methanol and ammonium formate (2 mmol l(-1), pH 3.4) and multiple reaction monitoring for the analytes on a triple-quadrupole mass spectrometer. The detection limit was 13 pg ml(-1) for BDP and B17P, 25 pg ml(-1) for BOH and 50 pg ml(-1) for B21P in plasma and 25 pg ml(-1) for BOH in urine. The method was successfully applied to the analysis of equine plasma and urine samples for the analytes following administration of BDP to horses by inhalation. B17P, the major and active metabolite of BDP, was detected and quantified in equine plasma up to 4 h post-administration by inhalation of a very low therapeutic dose (325 microg per horse) of BDP.


Asunto(s)
Beclometasona/análisis , Cromatografía Líquida de Alta Presión/métodos , Glucocorticoides/análisis , Caballos , Espectrometría de Masa por Ionización de Electrospray/métodos , Administración por Inhalación , Animales , Beclometasona/administración & dosificación , Beclometasona/farmacocinética , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/farmacocinética
19.
Rapid Commun Mass Spectrom ; 16(16): 1590-4, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12203252

RESUMEN

A screening method was developed to monitor the illegal use of synthetic corticosteroids in cattle. Diethyl ether extracts from spiked feces samples were cleaned-up by solid phase extraction followed by semipreparative reversed-phase chromatography (RPC). The fraction containing the corticosteroids was derivatized with ethoxyamine hydrochloride. The corresponding ethoximes were separated using silica-based C18 RPC and analyzed on-line in an ion trap mass spectrometer using atmospheric pressure positive chemical ionization. Ethoxime derivatives of dexamethasone and betamethasone were baseline resolved, allowing for the simultaneous mass spectrometric differentiation of both epimers in bovine feces by conventional non-chiral chromatography. At the lowest level tested (1 micro g/kg), corticosteroids (except triamcinolone) could be identified in compliance with the recent European criteria for residue identification. The quantitative performance of the method was best at residue levels > or = 2 micro g/kg.


Asunto(s)
Betametasona/análisis , Cromatografía Líquida de Alta Presión/métodos , Dexametasona/análisis , Heces/química , Glucocorticoides/análisis , Espectrometría de Masas/métodos , Animales , Beclometasona/análisis , Bovinos , Flumetasona/análisis , Tamizaje Masivo/métodos , Metilprednisolona/análisis , Prednisolona/análisis , Prednisona/análisis , Triamcinolona/análisis
20.
Int J Pharm ; 212(1): 109-19, 2001 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-11165826

RESUMEN

The purpose of this study was to examine the methodologies that may be used to estimate the maximum incorporation (<5 mole% drug) of beclomethasone dipropionate (BDP) in dipalmitoylphosphatidylcholine (DPPC) multilamellar liposomes. Two approaches are described. First, differential interference contrast (DIC) microscopy and cross-polarisation microscopy have been used to measure the concentration at which BDP crystals become apparent in BDP-containing liposome preparations, thereby allowing a semi-quantitative but simple estimation of entrapment. An alternative method is described whereby the unentrapped solid drug is separated from the liposomes via suspension in D2O, followed by centrifugation and HPLC analysis. The method resulted in an estimate of 1.5-2 mole% BDP, while the HPLC method yielded a value of 2.52 mole% BDP.


Asunto(s)
Antiinflamatorios/análisis , Beclometasona/análisis , 1,2-Dipalmitoilfosfatidilcolina/administración & dosificación , Beclometasona/administración & dosificación , Cromatografía Líquida de Alta Presión , Cristalización , Portadores de Fármacos , Liposomas , Microscopía de Interferencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA